drugset / Trial / NCT00207129

Effect of Capecitabine on the Pharmacokinetics of BMS-247550 and BMS-247550 on the Pharmacokinetics of Capecitabine and Its Metabolites in Patients With Advanced Malignancies

NCT00207129

Phase 1 Completed 25 enrolled R-Pharm
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to test how BMS-247550 (ixabepilone) affects the removal of capecitabine from the body and how capecitabine affects the removal of BMS-247550 from the body.

Timeline

Start
2004-10
Primary completion
2005-12
Completion
2005-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 1000 mg/m2 Oral
Subject Ixabepilone Small molecule 40 mg/m2 Intravenous

Indications